Skip to main content
Erschienen in: Clinical Rheumatology 3/2018

11.11.2017 | Original Article

High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis

verfasst von: Christina Charles-Schoeman, David Meriwether, Yuen Yin Lee, Ani Shahbazian, Srinivasa T. Reddy

Erschienen in: Clinical Rheumatology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to evaluate oxidation products of arachidonic acid and linoleic acid in lipoproteins and synovial fluid (SF) from patients with active rheumatoid arthritis (RA) compared to non-RA controls. High-density lipoproteins (HDL) and low-density lipoproteins (LDL) were isolated from plasma using fast protein liquid chromatography and HDL was isolated from SF using dextran sulfate precipitation. 5-Hydroxyeicosatetraenoic acid (HETE), 12-HETE, 15-HETE, 9 hydroxyoctadecadienoic (HODE), and 13-HODE levels were measured in HDL, LDL, and SF by liquid chromatography–tandem mass spectrometry. HDL’s anti-inflammatory function, cholesterol levels, myeloperoxidase (MPO) and paraoxonase 1 (PON1) activities were determined as previously. 5-HETE, 15-HETE, 9-HODE, and 13-HODE levels were significantly increased in HDL and LDL from patients with active RA (n = 10) compared to healthy controls (n = 8) and correlated significantly with measures of systemic inflammation, particularly in HDL (r = 0.65–0.80, p values < 0.004). Higher HETES and HODES in HDL were also significantly correlated with impaired HDL function as measured by the HDL inflammatory index (HII) (r = 0.54–0.58; p values < 0.03). 15-HETE levels and MPO activity were higher in RA SF (n = 10) compared to osteoarthritis (OA) SF(n = 11), and HDL from RA SF had worse function compared to OA SF HDL (HII = 2.1 ± 1.9 and 0.5 ± 0.1), respectively (p < 0.05). Oxidation products of arachidonic acid and linoleic acid are increased in HDL and LDL from patients with active RA compared to healthy controls, and are associated with worse anti-oxidant function of HDL. These results suggest a potential mechanism by which oxidative stress from active RA increases oxidized fatty acids in HDL, promoting HDL dysfunction, and thereby increasing atherosclerotic risk.
Literatur
1.
Zurück zum Zitat Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11(12):693–704CrossRefPubMed Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11(12):693–704CrossRefPubMed
2.
Zurück zum Zitat Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873CrossRefPubMed Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873CrossRefPubMed
3.
Zurück zum Zitat Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144(4):249–256CrossRefPubMed Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144(4):249–256CrossRefPubMed
4.
Zurück zum Zitat Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732CrossRefPubMed Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732CrossRefPubMed
5.
Zurück zum Zitat Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMed Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMed
7.
Zurück zum Zitat Kakinuma T, Yasuda T, Nakagawa T, Hiramitsu T, Akiyoshi M, Akagi M et al (2004) Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum 50(11):3495–3503CrossRefPubMed Kakinuma T, Yasuda T, Nakagawa T, Hiramitsu T, Akiyoshi M, Akagi M et al (2004) Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum 50(11):3495–3503CrossRefPubMed
8.
Zurück zum Zitat Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM et al (2010) L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 4(3):139–148CrossRefPubMedPubMedCentral Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM et al (2010) L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 4(3):139–148CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM et al (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60(10):2617–2623CrossRefPubMedPubMedCentral Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM et al (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60(10):2617–2623CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Berliner JA, Watson ADA (2005) Role for oxidized phospholipids in atherosclerosis. N Engl J Med 353(1):9–11CrossRefPubMed Berliner JA, Watson ADA (2005) Role for oxidized phospholipids in atherosclerosis. N Engl J Med 353(1):9–11CrossRefPubMed
11.
Zurück zum Zitat Morgantini C, Meriwether D, Baldi S, Venturi E, Pinnola S, Wagner AC et al (2014) HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 24(6):594–599CrossRefPubMedPubMedCentral Morgantini C, Meriwether D, Baldi S, Venturi E, Pinnola S, Wagner AC et al (2014) HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 24(6):594–599CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D et al (2014) Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 130(9):776–785CrossRefPubMedPubMedCentral Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D et al (2014) Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 130(9):776–785CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ross DJ, Hough G, Hama S, Aboulhosn J, Belperio JA, Saggar R et al (2015) Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. Pulm Circ 5(4):640–648CrossRefPubMedPubMedCentral Ross DJ, Hough G, Hama S, Aboulhosn J, Belperio JA, Saggar R et al (2015) Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. Pulm Circ 5(4):640–648CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41(9):1495–1508PubMed Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41(9):1495–1508PubMed
15.
Zurück zum Zitat Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41(9):1481–1494PubMed Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L et al (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41(9):1481–1494PubMed
16.
Zurück zum Zitat Oram JF, Yokoyama S (1996) Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37(12):2473–2491PubMed Oram JF, Yokoyama S (1996) Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37(12):2473–2491PubMed
17.
Zurück zum Zitat Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, Fitzgerald J, Ranganath VK et al (2012) Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71(7):1157–1162CrossRefPubMedPubMedCentral Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, Fitzgerald J, Ranganath VK et al (2012) Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71(7):1157–1162CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D et al (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60(10):2870–2879CrossRefPubMedPubMedCentral Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D et al (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60(10):2870–2879CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AMA (2001) Cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42(8):1308–1317PubMed Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AMA (2001) Cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42(8):1308–1317PubMed
20.
Zurück zum Zitat Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM et al (2007) Effects of high-dose atorvastatin on Antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34(7):1459–1464PubMed Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM et al (2007) Effects of high-dose atorvastatin on Antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34(7):1459–1464PubMed
21.
Zurück zum Zitat Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK et al (2013) Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65(11):2765–2772CrossRefPubMedPubMedCentral Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, Fitzgerald J, Ranganath VK et al (2013) Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65(11):2765–2772CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Aviram M, Rosenblat M (2008) Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 477:259–276CrossRefPubMed Aviram M, Rosenblat M (2008) Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 477:259–276CrossRefPubMed
23.
Zurück zum Zitat Kang LT, Phillips TM, Vanderhoek JY (1999) Novel membrane target proteins for lipoxygenase-derived mono(S)hydroxy fatty acids. Biochim Biophys Acta 1438(3):388–398CrossRefPubMed Kang LT, Phillips TM, Vanderhoek JY (1999) Novel membrane target proteins for lipoxygenase-derived mono(S)hydroxy fatty acids. Biochim Biophys Acta 1438(3):388–398CrossRefPubMed
24.
Zurück zum Zitat Vangaveti V, Baune BT, Kennedy RL (2010) Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab 1(2):51–60CrossRefPubMedPubMedCentral Vangaveti V, Baune BT, Kennedy RL (2010) Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab 1(2):51–60CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rothe T, Gruber F, Uderhardt S, Ipseiz N, Rossner S, Oskolkova O et al (2015) 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest 125(5):1944–1954CrossRefPubMedPubMedCentral Rothe T, Gruber F, Uderhardt S, Ipseiz N, Rossner S, Oskolkova O et al (2015) 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest 125(5):1944–1954CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF et al (1999) Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103(11):1597–1604CrossRefPubMedPubMedCentral Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF et al (1999) Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103(11):1597–1604CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T (2004) Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 50(6):1734–1739CrossRefPubMed Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T (2004) Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 50(6):1734–1739CrossRefPubMed
28.
Zurück zum Zitat Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G et al (2012) Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G et al (2012) Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum
29.
Zurück zum Zitat Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G et al (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108(22):2751–2756CrossRefPubMed Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G et al (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108(22):2751–2756CrossRefPubMed
30.
Zurück zum Zitat Khera AV, Cuchel M, de Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127–135CrossRefPubMedPubMedCentral Khera AV, Cuchel M, de Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127–135CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265–1276CrossRefPubMed Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265–1276CrossRefPubMed
32.
Zurück zum Zitat Jira W, Spiteller G, Carson W, Schramm A (1998) Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chem Phys Lipids 91(1):1–11CrossRefPubMed Jira W, Spiteller G, Carson W, Schramm A (1998) Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chem Phys Lipids 91(1):1–11CrossRefPubMed
33.
Zurück zum Zitat Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M et al (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114(4):529–541CrossRefPubMedPubMedCentral Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M et al (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114(4):529–541CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Gheorghe KR, Korotkova M, Catrina AI, Backman L, af KE, Claesson HE et al (2009) Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther 11(3):R83CrossRefPubMedPubMedCentral Gheorghe KR, Korotkova M, Catrina AI, Backman L, af KE, Claesson HE et al (2009) Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther 11(3):R83CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Scanu A, Oliviero F, Gruaz L, Sfriso P, Pozzuoli A, Frezzato F et al (2010) High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther 12(1):R23CrossRefPubMedPubMedCentral Scanu A, Oliviero F, Gruaz L, Sfriso P, Pozzuoli A, Frezzato F et al (2010) High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther 12(1):R23CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D, Apolipoprotein A-I (2004) Infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 6(6):R563–R566CrossRefPubMedPubMedCentral Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D, Apolipoprotein A-I (2004) Infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 6(6):R563–R566CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Mackness B, Hunt R, Durrington PN, Mackness MI (1997) Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17(7):1233–1238CrossRefPubMed Mackness B, Hunt R, Durrington PN, Mackness MI (1997) Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17(7):1233–1238CrossRefPubMed
38.
Zurück zum Zitat Ananth L, Prete PE, Kashyap ML, Apolipoproteins A-I (1993) B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism 42(7):803–806CrossRefPubMed Ananth L, Prete PE, Kashyap ML, Apolipoproteins A-I (1993) B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism 42(7):803–806CrossRefPubMed
39.
Zurück zum Zitat Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A et al (2009) Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 27(1):79–83PubMed Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A et al (2009) Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 27(1):79–83PubMed
40.
Zurück zum Zitat Prete PE, Gurakar-Osborne A, Kashyap ML (1993) Synovial fluid lipoproteins: review of current concepts and new directions. Semin Arthritis Rheum 23(2):79–89CrossRefPubMed Prete PE, Gurakar-Osborne A, Kashyap ML (1993) Synovial fluid lipoproteins: review of current concepts and new directions. Semin Arthritis Rheum 23(2):79–89CrossRefPubMed
41.
Zurück zum Zitat Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM et al (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70(3):482–487CrossRefPubMedPubMedCentral Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM et al (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70(3):482–487CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G et al (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105(3):290–292CrossRefPubMed Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G et al (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105(3):290–292CrossRefPubMed
Metadaten
Titel
High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis
verfasst von
Christina Charles-Schoeman
David Meriwether
Yuen Yin Lee
Ani Shahbazian
Srinivasa T. Reddy
Publikationsdatum
11.11.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 3/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3896-y

Weitere Artikel der Ausgabe 3/2018

Clinical Rheumatology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.